Cisatracurium-induced neuromuscular blockade is affected by chronic phenytoin or carbamazepine treatment in neurosurgical patients

Anesthesia and Analgesia

Volumn 100, Issue 2, 2005, Pages 538-544

  Richard, Anouk ^a   Girard, François ^a   Girard, Dominique C ^a   Boudreault, Daniel ^a   Chouinard, Philippe ^a   Moumdjian, Robert ^a   Bouthilier, Alain ^a   Ruel, Monique ^a   Couture, Johanne ^b   Varin, France ^b  

^a NOTRE DAME HOSPITAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CISATRACURIUM; PHENYTOIN;

ADULT; AGED; ANTICONVULSANT THERAPY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; DEMOGRAPHY; DRUG CROSS REACTIVITY; DRUG EFFECT; FEMALE; HUMAN; INTRAOPERATIVE PERIOD; MALE; MUSCLE TWITCH; NEUROMUSCULAR BLOCKING; NEUROSURGERY; PRIORITY JOURNAL; STANDARDIZATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STEADY STATE;

ADOLESCENT; ADULT; AGED; ANESTHESIA, GENERAL; ANTICONVULSANTS; ATRACURIUM; CARBAMAZEPINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; ELECTRIC STIMULATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MONITORING, INTRAOPERATIVE; NERVE BLOCK; NEUROMUSCULAR NONDEPOLARIZING AGENTS; NEUROSURGICAL PROCEDURES; PHENYTOIN; SYNAPTIC TRANSMISSION;

EID: 19944431486     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ANE.0000143333.84988.50     Document Type: Article

References (31)

1. Spacek A, Neiger FX, Krenn CG, et al. Rocuronium-induced neuromuscular block is affected by chronic carbamazepine therapy. Anesthesiology 1999;90:109-12.
2. Hickey DR, Sangwan S, Bevan JC. Phenytoin-induced resistance to pancuronium. Anesthesia 1988;43:757-9.
3. Koenig HM, Hoffman WE. The effect of anticonvulsant therapy on two doses of rocuronium-induced neuromuscular blockade. J Neurosurg Anesthesiol 1999;2:86-9.
4. Roth S, Ebrahim ZY. Resistance to pancuronium in patients receiving carbamazepine. Anesthesiology 1987;66:691-3.
5. Kim CS, Ardnold FJ, Iani MS, et al. Decreased sensitivity to metocurine during long-term phenytoin therapy may be attributable to protein binding and acetylcholine receptor changes. Anesthesiology 1992;77:500-6.
6. Alloul K, Whalley DG, Shutway, et al. Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. Anesthesiology 1996;84: 330-9.
7. Tempolhoff R, Modica PA, Jellish WS, Spitznagel EL. Resistance to atracurium-induced neuromuscular blockade in patients with intractable seizure disorders treated with anticonvulsants. Anesth Analg 1990;71:665-9.
8. Spacek A, Neiger FX, Spiss CK, Kress HG. Atracurium-induced neuromuscular block is not affected by chronic anticonvulsant therapy with carbamazepine. Acta Anesthesiol Scand 1997;41: 1308-11.
9. Ornstein E, Atteo RS, Schwartz AE, et al. The effect of phenytoin on the magnitude and duration of neuromuscular block following atracurium or vecuronium. Anesthesiology 1987;67:191-6.
10. 1-isomer of atracurium, in human and rat plasma. Clin Pharmacol Ther 1995;58:132-42.
11. De Wolf AM, Freeman JA, Scott VL, et al. Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. Br J Anaesth 1996;76:624-8.
12. Lien CA, Schmith VD, Belmont MR, et al. Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1996;84:300-8.
13. Ornstein E, Lien CA, Matteo RS, et al. Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. Anesthesiology 1996;84:520-5.
14. Kisor DF, Schimth VD, Wargin WA, et al. Importance of the organ-independent elimination of cis-atracurium. Anesth Analg 1996;83:1065-71.
15. Koenig HM, Edwards TL. Cis-atracurium-induced neuromuscular blockade in anticonvulsant treated neurosurgical patients. J Neurosurg Anesthesiol 2000;12:314-8.
16. Viby-Mogensen J, Englbaek J, Eriksson LI, et al. Good clinical research practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents. Acta Anaesthesiol Scand 1996;40: 59-74.
17. Viby-Mogensen J, Ostergaard D, Donati F, et al. Pharmacokinetic studies of neuromuscular blocking agents: good clinical research practice (GCRP). Acta Anaesthesiol Scand 2000;44: 1169-90.
18. Lee GC, Lyengar S, Szenohradszky J, el at. Improving the design of muscle relaxant studies. Anesthesiology 1997;86:48-54.
19. Bryant BJ, James CD, Cook DR, Harrelson JC. High performance liquid chromatography assay for cisatracurium and its metabolites in human urine. J Liq Chromatogr Relat Technol 1997;20: 2041-51.
20. Cameron M, Donati F, Varin F. In vitro plasma protein binding of neuromuscular blocking agents in different subpopulations of patients. Anesth Analg 1995;81:1019-25.
21. Belmont MR, Lien CA, Quessy S, et al. The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1995;82: 1139-45.
22. Eastwood NB, Boyd AH, Parker CJR, Hunter JM. Pharmacokinetics of IR-cis 1'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure. Br J Anaesth 1995;75:431-5.
23. Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998;32:554-63.
24. Pirttiaho HI, Sotaniemi EA, Pelkonen RO, Pitkanen U. Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants. Eur J Clin Pharmacol 1982;22:441-5.
25. Pirttiaho HI, Sotaniemi EA, Ahokas JT, Pitkanen U. Liver size and indices of drug metabolism in epileptics. Br J Clin Pharmacol 1978;6:273-8.
26. Tran VT, Fiset P, Varin F. Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. Anesth Analg 1998;87:1158-63.
27. Bergeron L, Bevan DR, Berrill A, et al. Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. Anesthesiology 2001;95:314-23.
28. Alderdice MT, Trommer BA. Differential effects of the anticonvulsants phenobarbital, ethosuximide and carbamazepine on neuromuscular transmission. J Pharmacol Exp Ther 1980;215: 92-6.
29. Gage PW, Lonergan M, Torda TA. Presynaptic and postsynaptic depressant effects of phenytoin sodium at the neuromuscular junction. Br J Pharmacol 1980;69:119-21.
30. Nguyen A, Ramzan I. Acute in vitro neuromuscular effects of carbamazepine and carbamazepine-10,11-epoxide. Anesth Analg 1997;84:886-90.
31. Cammu G. Interactions of neuromuscular blocking drugs. Acta Anaesthesiol Belg 2001;52:357-63.